UNASSIGNED: 90 Background: Biochemical recurrence (BCR) may be an indicator of @entity263 ; however, it isn't specific enough to differentiate @entity1 who will experience rapid onset of @entity3 from those who do not. Such lack of specificity leads to overtreatment of @entity1 who will likely never experience @entity3 in their lifetime. We hypothesize that genomic biomarkers, detectable in primary @entity5 tissue, may better identify rapidly progressing @entity263 . METHODS: FFPE prostatectomy specimens (n = 309) from the Mayo @entity5 registry were profiled using a high-density expression array. @entity1 were retrospectively classified into three outcome groups: NED (no evidence of disease recurrence); BCR-only ( @entity1 that experienced BCR but no metastatic progression); and MET ( @entity3 confirmed by positive CT or bone scans) and were matched on several criteria for analysis . Uni- and multi-variable analyses between outcome groups were used to analyze clinical and genomic variables (adjusting for adjuvant hormone therapy as a confounding factor). RESULTS: Median follow-up was 16.8 years and MET @entity1 were diagnosed a mean of 3.1 years following BCR. Univariable and multivariable analysis of clinical variables failed to show statistically significant differences between NED and BCR-only outcome groups. Differential expression analysis between NED and BCR-only groups showed no significant differences after false discovery correction. Conversely, 6,277 and 52,020 biomarkers were differentially expressed between MET and the BCR-only and NED groups, respectively. CONCLUSIONS: Considering the clinical and genomic results together, @entity1 who experienced rapid @entity3 were significantly different from both the NED and BCR-only groups. However, no significant differences were identified between the BCR-only and NED outcome groups. These results imply that BCR is not a good surrogate for @entity1 who are likely to experience rapid onset of @entity3 and @entity263 .

Clinical and genomic analysis of XXXX progression in a background of biochemical recurrence.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'men'] @entity263 :: ('MESH:D011471', 'Disease') :: ['metastatic prostate cancer', 'lethal prostate cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Clinic tumor'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases', 'metastatic disease']
@entity3 :: (MESH:D009362,Disease) :: ['metastatic disease']
